Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Momentum returns as biotech enters next phase ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

The German pharmaceutical company Merck is in talks to acquire the assets of the American SpringWorks Therapeutics Inc. at a price of $47 per share. This is reported in a press release from Merck. As ...

The second quarter of 2025 was a period of dynamic evolution within the biotech and pharma sectors. Critical factors like escalating policy pressures, pipeline pivots by leading companies and the ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

Now a summer staple in Stratford, the World in a Weekend: International Puppet Festival is pushing itself to the limit by adding a fifth day of programming while welcoming performers from all corners ...